Clinical trial
A Phase 1, Open-label, Randomized, Crossover Design Clinical Trial in Healthy Normal Volunteers to Evaluate Insulin Exposure and Effect Following Inhalation of Technosphere® Insulin Inhalation Powder at Multiple Doses Using the Gen2C Inhaler
NCT01490762 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label, Randomized, Crossover Design Clinical Trial in Healthy Normal Volunteers to Evaluate Insulin Exposure and Effect Following Inhalation of Technosphere® Insulin Inhalation Powder at Multiple Doses Using the Gen2C Inhaler
- Lead sponsor
- Mannkind Corporation
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2011
- Completion date
- July 31, 2012
- Enrollment
- 35 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy